Global Pharma Developments: IPOs, Bird Flu, and Gene Therapies

This roundup covers key developments in global health: Anthem Biosciences files a $397 million IPO amid investor interest, France loses bird flu-free status, China defends COVID-19 data sharing, and major pharmaceutical firms like Novartis and Merck see significant advances in gene therapy and drug approvals.

This week in health news, Indian contract drugmaker Anthem Biosciences took significant steps by filing for a $397 million initial public offering. This move coincides with a booming year for stock market listings. Among its backers are True North and DavosPharma, indicating robust investor interest in this sector.

In Europe, France finds itself battling bird flu once again, following recently declared disease-free status. The resurgence of highly pathogenic avian influenza on two farms has renewed concerns, particularly as losses in the US have driven up egg prices and posed threats to livestock and human health.

On the international stage, China's commitment to COVID-19 data transparency is under scrutiny. Responding to the WHO's calls for greater access, the country's foreign ministry emphasized its openness in sharing research findings, citing multiple expert engagements.

(With inputs from agencies.)